STALLERGENES-GREER
18.5.2020 09:07:12 CEST | Business Wire | Press release
Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the expansion of the supply of subcutaneous products (SCIT), further broadening its offering to patients and the medical community through a sustained investment in quality and operational excellence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200518005223/en/
“Stallergenes Greer is committed to the disciplined execution of the company’s strategy and is well advanced on its transformation journey. Our robust fundamentals, investments in quality, and commitment to operational excellence continue to yield results as evidenced by the expansion of SCIT products, the widening of our portfolio and the solidifying of our leadership positions in various markets. We can be proud of our achievements and look ahead with confidence,” declares Michele Antonelli, Chief Executive Officer.
Acceleration of SCIT production
In April 2020, the French Agency for Medicines and Health (ANSM) lifted its injunction, which primarily impacted the production of subcutaneous products for the Europe and International region. SCIT production will fully resume in Antony, France, in the coming weeks, starting with skin prick tests (Alyostal® pricks) for diagnosis, and Alustal® for the treatment of patients with allergies. SCIT production in the US, where Stallergenes Greer continues to lead the market, has remained fully operational and was not part of the injunction.
With sustained investments in its global manufacturing capabilities, Stallergenes Greer operates state-of-the-art manufacturing and quality systems that meet the highest product quality standards.
Stallergenes Greer intends to further provide injectable forms with the resumption of Phostal®.
SCIT products meet the needs of patients whose profile and lifestyle require an alternative access to treatment and delivery mode, longer intervals between treatment, or monitoring of adherence by their physician.
Further broadening the allergen immunotherapy treatment portfolio
Stallergenes Greer remains determined to offer an extensive portfolio of treatment solutions tailored to each patient profile and to each market, including injectable therapies, sublingual therapies such as drops and tablets, venoms and diagnostics. From diagnosis to treatment, Stallergenes Greer’s portfolio is designed to ensure the consistency of its products in terms of active ingredients and high-quality standards. It allows physicians to choose the administration method which is best suited to each patient’s needs and lifestyle.
In 2019 alone, the company added 15 new Staloral® allergen references to its sublingual portfolio and will launch another 10 references in 2020.
Stallergenes Greer, also continued to enhance its tablet offering which already includes Oralair® for the treatment of grass pollen allergies and Actair® for the treatment of house dust mite allergies, which is distributed in selected countries of the Asia-Pacific region.
The company recently submitted a European marketing application authorisation for its house dust mite allergy immunotherapy tablet. The tablet is also under New Drug Submission review by Health Canada.
Stallergenes Greer is delivering on the disciplined execution of its strategy of providing people with allergies a broad range of personalised treatment options, which will make it both a company with a complete portfolio and a valued partner for patients and the medical community.
ABOUT STALLERGENES GREER Ltd
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
Additional information is available at https://www.stallergenesgreer.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005223/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press release
Canada becomes the 25th Allied nation to back the NATO Innovation Fund, gaining access to €1.1 billion in mission-aligned capital and a co-investor network spanning the Alliance Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the amb
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release
Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
